New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 3, 2003, Pages 267-272

  Langford, Carol A ^a   Balow, James E ^b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antineutrophil cytoplasmic autoantibodies (ANCA); Glomerulonephritis; Microscopic polyangiitis; Vasculitis; Wegener granulomatosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ANIMAL MODEL; B LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COLITIS; DIARRHEA; FATIGUE; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; META ANALYSIS; MOUSE; MYALGIA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; VASCULITIS; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; KIDNEY DISEASES; METHOTREXATE; MICE; MYCOPHENOLIC ACID; VASCULITIS;

EID: 0038290336     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200305000-00007     Document Type: Review

References (40)

1. Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13:1953-1960. An excellent recent update on pathogenetic mechanisms and state of the art of treatment of small vessel vasculitis.
2. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61:80-89.
3. Couser WG. Wegener granulomatosis. Sensitized cells come of age: a new era in renal immunology with important therapeutic implications. J Am Soc Nephrol 1999; 10:664-665.
4. Cunningham MA, Huang XR, Dowling JP, et al. Prominence of cell-mediated immunity effectors in 'pauci-immune' glomerulonephritis. J Am Soc Nephrol 1999; 10:499-506.
5. Specks, U. Are animal models of vasculitis suitable tools? Curr Opin Rheumatol 2000; 12:11-19.
6. + T cells specific to glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest 2002; 109:517-524. A sophisticated experimental approach to examining the pathogenic role of T cells in a model of anti-basement membrane disease.
7. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 1982; 288:606.
8. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1988; 1:425-429.
9. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an International Consensus Conference. Arthritis Rheum 1994; 37:187-192.
10. Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115-4119.
11. Woywodt A, Streiber F, deGroot K, et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361:206-210. A provocative study showing markedly increased numbers of necrotic endothelial cells in the circulation of patients with active vasculitis.
12. Falk RJ, Jennette JC. ANCA are pathogenic - Oh yes they are! J Am Soc Nephrol 2002; 13:1977-1979. Authoritative synopsis of the evidence of pathogenicity of ANCA.
13. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963. Major definitive article presenting compelling evidence of the pathogenic role of myeloperoxidase-specific ANCA in an innovative mouse model of small vessel vasculitis.
14. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295-300.
15. Nachman PH, Hogan SL, Jennette JC, et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33-39.
16. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666-675.
17. Fauci A, Wolff S. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine 1973; 52:535-561.
18. Fauci A, Haynes B, Katz P, et al. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
19. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-494.
20. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021-1032.
21. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35:6112-6118.
22. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608-613.
23. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25:492-495.
24. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26:1134-1139.
25. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836-1840.
26. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666-2673. A prospective, standardized open-label trial examining the use of a staged therapeutic regimen utilizing cyclophosphamide for remission induction followed by methotrexate for remission maintenance.
27. Reinhold-Keller E, Fink CO, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47:326-332. This trial examines the use of methotrexate for maintenance of remission achieved with cyclophosphamide. This study found glomerulonephritis to be a feature of disease relapse in 16 patients, 14 of whom exhibited a rise in serum creatinine.
28. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13:48-55.
29. Nowack R, Göbel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10:1965-1971. This study reports the first prospective open-label data on the use of the mycophenolate mofetil in patients with Wegener's granulomatosis and microscopic polyangiitis.
30. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
31. Waiser J, Budde K, Braasch E, et al. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999; 34:e9.
32. Le Hello C, Bonte I, Mora JJ, et al. Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil. Rheumatology (Oxford) 2002; 41:236-237.
33. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57:421-424.
34. Maes B, Oellerich M, Ceuppens JL, et al. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2002; 17:923-926.
35. Woywodt A, Choi M, Schneider W, et al. Cytomegalovirus colitis during mycophenolate mofetil therapy for Wegener's granulomatosis. Am J Nephrol 2000; 20:468-472.
36. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154. Open-label phase I safety study of etanercept combined with standard therapies in Wegener's granulomatosis.
37. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNF-alpha blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61:559.
38. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
39. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-1307.
40. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44:2836-2840. An interesting case report of a patient with PR-3 ANCA positive Wegener's granulomatosis treated with rituximab.